ReleaseWire Connect

Vincent G. Brichard, Senior Vice President and Head of the Immunotherapeutics Business Unit at GlaxoSmithKline Biologicals will give a keynote presentation on the “Development of Active Immunization against Cancer: The Example of MAGE-A3” at the Immunotherapeutics Partnering and Deal-making Conference to be held in San Diego, CA on January 30-31, 2012 by GTC.

Leslie J. Williams, President and CEO at ImmusanT will give a presentation on “ImmusanT’s Development of an Immunotherapeutic Vaccine for Celiac Disease” at the Immunotherapeutics Partnering and Deal-making Conference to be held in San Diego, CA on January 30-31, 2012 by GTC.

Jeremy Barton, Vice President of Precision Medicine at Pfizer Worldwide Research and Development, is giving a Keynote presentation entitled “Patient Selection Strategies for Targeted Therapies and Implementation into Clinical Study Designs” at the 3rd Cancer Targets and Therapeutics Conference to be held on February 27-28, 2012 in Las Vegas, NV by GTC. Also presenting at the conference is C. Glenn Begley, Vice President, Global Head of Hematology and Oncology Research at Amgen on “Challenges in Translating Preclinical Research into Benefit for Patients”.

C. Glenn Begley, Vice President and Global Head of Hematology and Oncology Research at Amgen, will be giving a featured presentation entitled “Challenges in Translating Preclinical Research into Benefit for Patients” at the 3rd Cancer Targets and Therapeutics Conference to be held on February 27-28, 2012 in Las Vegas, NV by GTC. Also presenting at the conference is Jeremy Barton, Vice President of Precision Medicine at Pfizer. Dr. Barton will be speaking on “Patient Selection Strategies for Targeted Therapies and Implementation into Clinical Study Designs”.

Jason Rhodes, Executive Vice President & Chief Business Officer at Epizyme and Michael Shih, Senior Director, Business Development at Eisai will give a featured joint presentation on “Open Innovation: Eisai and Epizyme’s Epigenetics Partnership” at the Oncology Partnering and Deal-making Conference to be held in Las Vegas, NV on February 27-28, 2012 by GTC.

Hospital Medical Center, will be giving a keynote presentation entitled “Breakthroughs in understanding the pathogenesis of the new allergic disease eosinophilic esophagitis and implications for drug development,” at the Allergy Drug Discovery and Development Conference to be held on January 30-31, 2012 in San Diego, CA by GTC.

Richard Hatchett, Chief Medical Officer and Deputy Director of BARDA and Joseph Larsen, Chief of the Broad Spectrum Antimicrobials (BSA) Program at BARDA will present on “Partnering and Working with BARDA” at the 8th Anti-infectives Partnering and Deal-making Conference to be held in Boston, MA on November 7-8, 2011 by GTC.

John H Rex, Vice President at AstraZeneca and David J. Payne, Vice President at GlaxoSmithKline will give keynote presentations at the 8th Anti-infectives Partnering and Deal-making Conference to be held in Boston, MA on November 7-8, 2011 by GTC.

Neil S. Ryder, Executive Director of Infectious Diseases at Novartis Institutes for BioMedical Research will give a featured presentation on “Opportunities and Challenges for Novel Antifungal Therapies” at the 8th Anti-infectives Partnering and Deal-making Conference to be held in Boston, MA on November 7-8, 2011 by GTC.

Michael G. Kurilla, Director, Office of BioDefense Research Affairs at NIAID, NIH will give a featured presentation on “Novel, Antiviral Host Based Targeting Influencing Drug Development” at the 8th Anti-infectives Partnering and Deal-making Conference to be held in Boston, MA on November 7-8, 2011 by GTC.